Abstract
Pharmaceutical iron oxide preparations have been used as MRI contrast agents for a variety of purposes. These agents predominantly decrease T2 relaxation times and therefore cause a decrease in signal intensity of tissues that contain the agent. After intravenous adminstration, dextran-coated iron oxides typically accumulate in phagocytic cells in liver and spleen. Clinical trials have shown that iron oxide increases lesion/liver and lesion/spleen contrast, that more lesions can be depicted than on plain MRI or CT, and that the size threshold for lesion detection decreases. Decreased uptake of iron oxides in liver has been observed in hepatitis and cirrhosis, potentially allowing the assessment of organ function. More recently a variety of novel, target-specific monocrydtalline iron oxides compounds have been used for receptor and immunospecific images. Future development of targeted MRI contrast agents is critical for organ- or tissue-specific quantitative and functional MRI.
Similar content being viewed by others
References
Weinmann HJ, Brasch RC, Press WR, Wesbey GE (1984) Characteristics of Gd-DTPA complex: a potential NMR contrast agent. AJR 142: 619–625
Brasch RC (1983) Work in progress: methods of contrast enhancement for NMR imaging and potential application. Radiology 147: 781–788
Brasch RC, Weinmann HJ, Wesbey GE (1984) Contrast-enhanced NMR imaging: animal studies using gadolinium-DTPA complex. AJR 142: 625–630
Brasch RC, Bennet HF (1988) Considerations in the choice of contrast media for MR imaging. Radiology 166: 897–899
Brasch RC (1992) New directions in the development of MR imaging contrast media. Radiology 183: 1–11
Gillis P, Koenig SH (1987) Transverse relaxation of solvent protons induced by magnetized spheres: application to ferritin, erythrocytes and magnetite. Magn Reson Med 5: 323–345
Fretz CJ, Elizondo G, Weissleder R, Hahn PF, Stark DD, Ferrucci JT (1989) Superparamagnetic iron oxide-enhanced MR imaging: pulse sequence optimization for detection of liver cancer. Radiology 172: 393–397
Bean CP, Livingston JD (1959) Superparamagnetism. J Appl Phys 30: 120S-129S
Widder DJ, Greif WL, Widder KJ, Edelman RR, Brady TJ (1987) Magnetite albumin microspheres: a new MR contrast material. AJR 148: 399–404
Carr HY, Purcell EM (1954) Effect of diffusion on free precession in nuclear magnetic resonance experiments. Phys Rev 94: 630–637
Majumdar S, Zoghbi S, Pope CF, Gore JC (1988) Quantitation of MR relaxation effects on iron oxide particles in liver and spleen. Radiology 169: 653–655
Majumdar S, Zoghbi S, Pope CF, Gore JC (1989) A quantitative study of relaxation rate enhancement produced by iron oxide particles in polyacrylamide gels and tissue. Magn Reson Med 9: 185–202
Hardy PA, Henkelman RM (1989) Transverse relaxation rate enhancement caused by magnetic particulates. Magn Reson Imaging 7: 265–275
Rozenman Y, Zou XM, Kantor HL (1990) Cardiovascular MR imaging with iron oxide particles: utility of a superparamagnetic contrast agent and the role of diffusion in signal loss. Radiology 175: 655–659
Ohghushi M, Nagayama K, Wada A (1978) Dextran magnetite: a new relaxation agent and its application to T2-measurements in gel systems. J Magn Reson 29: 599–601
Wolf GL, Burnett KR, Goldstein EJ, Joseph PM (1985) Contrast agents for magnetic resonance imaging. In: Magnetic resonance annual. New York: Raven Press, 1985
Mendoca-Dias MH, Lauterbur PC (1986) Ferromagnetic particles as contrast agents for magnetic resonance imaging of the liver and spleen. Magn Reson Med 3: 328–330
Josephson L, Lewis L, Jacobs P, Hahn PF, Stark DD (1988) The effects of iron oxides on proton relaxivity. Magn Reson Imaging 6: 647–653
Weissleder R, Stark DD, Compton CC, Wittenberg J, Ferrucci JT (1987) Ferrite-enhanced MR imaging of hepatic lymphoma: an experimental study in rats. AJR 149: 1161–1165
Magin RL, Bacic G, Alameda JC, Neisman MR, Wright SM, Swartz HM (1988) Dextran magnetite as a liver contrast agent. In: Society of Magnetic Resonance in Medicine, Seventh Annual Meeting, San Francisco
Stark DD, Weissleder R, Elizondo G et al (1988) Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology 168: 297–301
Fahlvik AK, Holtz E, Leander P, Schroder U, Klaveness J (1990) Magnetic starch microspheres: efficacy and elimination of a new organ-specific contrast agent for magnetic resonance imaging. Invest Radiol 25: 113–120
Maas R, Spielman RP, Bonacker M, et al (1991) Utrasmall magnetic particles coated with polyethyleneglycol as contrast agent in MRI of experimental abscesses: an animal study in mini-pigs. In: Society of Magnetic Resonance in Medicine, Tenth Annual Meeting, San Francisco, p 505
Pouliquen D, Le Jeune JJ, Perdrisot R, Erimas A, Jallet P (1991) Iron oxide nanoparticles for use as an MRI contrast agent: pharmacokinetics and metabolism. Magn Reson Imaging 9: 275–283
Pouliquen D, Perroud H, Calza F, Jallet P, Le Jeune JJ (1992) Investigation of the magnetic properties of iron oxide nanoparticles used as a contrast agent. Magn Reson Med 24: 75–84
Weissleder R, Hahn PF, Stark DD, et al (1988) Superparamagnetic iron oxide: enhanced detection of focal splenic tumors with MR imaging. Radiology 169: 399–403
Hahn PF, Stark DD, Lewis JM, et al (1989) First clinical trial of a new superparamagnetic iron oxide for use as an oral superparamagnetic contrast agent in MR imaging. Radiology 175: 695–700
Rinck PA, Smevik O, Nilsen G, et al (1991) Oral magnetic particles in MR imaging of the abdomen and pelvis. Radiology 178: 775–779
Weissleder R, Papisov M (1992) Pharmaceutical iron oxides for MR imaging. Magn Reson Rev 4: 1–20
Molday RS, Mackenzie D (1982) Immunospecific ferromagnetic iron-dextran reagents for the labelling and magnetic separation of cells. J Immunol Methods 52: 353–367
Molday RS, Molday LL (1984) Separation of cells labeled with immunospecific iron dextran microspheres using high gradient magnetic chromatography. FEBS Lett 170: 232–238
Misawa T, Hashimoto K, Shimodaira S (1973) Formation of Fe(II)-Fe(III) intermediary grenn complex on oxidation of ferrous iron in neutral and slightly alkaline sulphate solutions. J Inorg Nucl Chem 35: 4107–4174
Papisov MI, Savelyev VY, Sergienko VB, Torchilin VP (1987) Magnetic drug targeting. I. In vivo kinetics of radiolabelled magnetic drug carriers. Int J Pharmacokinetics 40: 201–206
Papisov MI, Torchilin VP (1987) Magnetic drug targeting. I. Targeted drug transport by magnetic microparticles: factors influencing therapeutic effect. Int J Pharmacokinetics 40: 207 -214
Weissleder R, Stark DD, Engelstad BL, et al (1989) Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR 152: 167–173
Weissleder R, Lee AS, Fischman AJ, et al (1991) MR antibody imaging: polyclonal human IgG labelled with polymeric iron oxide. Radiology 181: 245–249
Reimer P, Kwong KK, Weisskoff R, Cohen MS, Brady TJ, Weissleder R (1992) Dynamic signal changes in liver with superparamagnetic MR contrast agents. J Magn Reson Imaging 2: 177–181
Josephson L, Bigler J, White D (1991) The magnetic properties of some materials affecting MR images. In: Workshop on contrast-enhanced magnetic resonance, Napa, California, 1991
Hershko C, Cook JD, Finch CA (1973) Storage iron kinetics. III. Study of desferrioxamine action by selective radioiron labels of RE and parenchymal cells. J Lab Clin Med 81: 876–886
Tavill AS, Bacon BR (1986) Hemochromatosis: how much is too much. Hepatology 6: 142–145
Weir MP, Gibson JF, Peters TJ (1984) Haemosiderosis and tissue damage. Cell Biochem Funct 2: 186–194
Bassett ML, Halliday JW, Powell LW (1986) Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology 6: 24–29
Kawamura Y, Endo K, Watanabe Y, et al (1990) Use of magnetite particles as a contrast agent for MR imaging of the liver. Radiology 174: 357–360
Josephson L, Groman EV, Menz LI, Luis JM, Bengele H (1990) A functionalized superparamagnetic iron oxide colloid as a receptor directed MR contrast agent. Magn Reson Imaging 8: 637–646
Niederau C, Fischer R, Sonnenberg A, Steremmel W, Trampisch HJ, Strohmeyer G (1985) Survival and causes of death in cirrhotic patients with primary hemochromatosis. N Engl J Med 313: 1256–1262
Bacon BR, Stark DD, Park CH, et al (1987) Ferrite particles: a new magnetic resonance imaging contrast agent. Lack of acute or chronic hepatoxicity after intravenous administration. J Lab Clin Med 110: 164–171
Snyder WS, Cook MJ, Nasset ES, Karhausen LR, Howells GP, Tipton IH (1974) Report of the task group on reference man. In: Report of the tark group and reference man. Oxford: Pergamon Press, 1974
Tsang YM, Stark DD, Chen MCM, Weissleder R, Wittenberg J, Ferrucci JT (1988) Hepatic micrometastasis in the rat: ferrite-enhanced MR imaging. Radiology 167: 21–24
Weissleder R, Stark DD, Compton CC, Ferrucci JT (1987) MRI of hepatic lymphoma: an experimental study in rodents using ferrite. AJR 149: 1161–1165
Weissleder R, Saini S, Stark DD, et al (1988) Pyogenic liver abscess: contrast-enhanced MR imaging in rats. AJR 150: 115–120
Magin RL, Bacic G, Neisman MR, Alameda JC, Wright SM, Swartz HM (1990) Dextran magnetite as a liver contrast agent. Magn Reson Med 20: 1–16
Marchal GY, Hecke P van, Demaerel P, et al (1989) Detection of liver metastases with superparamagnetic iron oxides in 15 patients. AJR 152: 771–775
Elizondo G, Weissleder R, Stark DD, et al (1990) Hepatic cirrhosis and hepatitis: MR imaging enhanced with superparamagnetic iron oxide. Radiology 174: 797–801
Clement O, Frija G, Chambon C, Schouman-Claeys E (1992) Superparamagnetic iron oxide-enhanced magnetic resonance imaging of experimental liver tumors after mitomycin C administration. Invest Radiol 27: 230–235
Weissleder R, Reimer P, Lee AS, Wittenberg J, Brady TJ (1990) MR receptor imaging: ultrasmall iron oxide particles targeted to asialoglycoprotein receptors. AJR 155: 1161–1167
Meijer DKF, Sluijs P van der (1987) The influence of binding to albumin and α1-binding glycoprotein on the clearance of drugs by the liver. Pharm Weekbl [Sci] 9: 65–74
Stockert RJ, Becker FF (1980) Diminished hepatic binding protein for desialyted glycoproteins during chemical hepatocarcinogensis. Cancer Res 40: 3632–3634
Sobue G, Kosaka A (1980) Asialoglycoproteinemia in a case of primary hepatic cancer. Hepatogastroenterology 27: 200–203
Marshall JS, Williams S, Jones P, Hepner GW (1978) Serum desialyted glycoproteins in patients with hepatobiliary dysfunction. J Lab Clin Med 92: 30–37
Sawamura T, Nakada H, Shiozaki Y, Sameshima Y, Tashiro Y (1984) Hy[erasialoglycoproteinemia in patients with chronic liver disease and/or liver cell carcinoma. Gastroenterology 87: 1217–1221
Blouin A, Bolender RP, Weibel ER (1977) Distribution of organelles and membranes between hepatocytes and non-hepatocytes in the rat liver parenchyma. J Cell Biol 72: 441–455
Knook DL, Sleyster EC (1977) In: Wisse E, Knook DL (eds) Kupffer cells and other liver sinusoidal cells. Amsterdam: Elsevier/North-Holland, 1977
Reimer P, Weissleder R, Lee AS, Wittenberg J, Brady TJ (1990) Receptor imaging: application to MR imaging of liver cancer. Radiology 177: 729–734
Baumann P, Eap CB, Mueller WE, Tillement JP (1989) Alpha1-acid glycoprotein: genetics, biochemistry, physiological functions, and pharmacology. In: Alpha1-acid glucoprotein. Genetics, biochemistry, physiological functions, and pharmacology. New York: Alan R. Liss, Inc. 1989
Reimer P, Weissleder R, Brady TJ, et al (1991) MR receptor imaging of experimental hepatocellular carcinoma. Radiology 180: 641–645
Reimer P, Weissleder R, Brady TJ, et al (1991) Experimental hepatocellular carcinoma: MR receptor imaging. Radiology 180: 641–645
Reimer P, Weissleder R, Lee AS, Buettner S, Wittenberg J, Brady TJ (1991) Asialoglycoprotein receptor function in benign liver disease: evaluation with MR imaging. Radiology 178: 769–774
Murphy FB, Barefield KP, Steinberg HV, Bernardino ME (1988) CT-or sonography-guided biopsy of the liver in the presence of ascites: frequency of complications. AJR 151: 485–486
Kudo M, Todo A, Ikekubo K, et al (1987) Estimation of hepatic functional reserve by asialoglycoprotein receptor-binding, radiolabeled synthetic ligand “Tc-99m-galactosyl-neoglycolalbumin”. Jpn J Nucl Med 24: 1653–1662
Kubota Y, Kojima M, Hazama H, et al (1986) A new liver function test using the asialoglycoprotein-receptor system on the liver cell membrane. I. Evaluation of liver imaging using the Tc-99m-neoglycoprotein. Jpn J Nucl Med 23: 899–905
Kawa S, Hazama H, Kojima M, et al (1986) A new liver function test using the asialoglycoprotein-receptor system on the liver cell membrane. II. Quantitative evaluation of labeled neoglycoprotein clearance. Jpn J Nucl Med 23: 907–916
Hazama H, Kawa S, Kubota Y, et al (1986) A new liver function test using the asialoglycoprotein-receptor system on the liver cell membrane. III. Evaluation for usefulness by liver function test using the Tc-99m-neoglycoprotein. Jpn J Nucl Med 23: 917–926
Woodle ES, Vera DR, Stadalnik RC, Ward RE (1987) Tc-NGA imaging in liver transplantation: preclinical studies. Surgery 102: 55–62
Weissleder R, Stark DD, Rummeny EJ, Compton CC, Ferrucci JT (1988) Splenic lymphoma: ferrite-enhanced MR imaging in rats. Radiology 166: 423–430
Weissleder R, Hahn P, Stark DD, et al (1987) MR imaging of splenic metastases: ferrite-enhanced detection in rats. AJR 149: 723–726
Weissleder R, Elizondo G, Stark DD, et al (1989) The diagnosis of splenic lymphoma by MR imaging: value of superparamagnetic iron oxide. AJR 152: 175–180
Weissleder R, Hahn PF, Stark DD, et al (1987) MRI of the spleen: ferrite enhanced detection of splenic metastases. AJR 149: 723–726
Weissleder R, Elizondo G, Wittenberg J, Rabito C, Bengele HH, Josephson L (1990) Ultrasmall superparamagnetic iron oxide (USPIO): characterization of a new class of MR contrast agents. Radiology 175: 489–493
Seneterre ES, Weissleder R, Jaramillo D, et al (1991) Bone marrow: ultrasmall superparamagnetic iron oxide for MR imaging. Radiology 179: 529–533
Weissleder R, Elizondo G, Josephson L, et al (1989) Experimental lymph node metastases: enhanced detection with MR lumphography. Radiology 171: 835–839
Weissleder R, Elizondo G, Wittenberg J, Lee AS, Josephson L, Brady TJ (1990) Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 175: 494–498
Taupitz M, Hamm B, Wagner S, Binder A, Wolf KJ (1991) MR lymphography using iron oxide particles: experimental studies in tumor-free and VX2 tumor-bearing rabbits. In: Society of Magnetic Resonance in Medicine, Tenth Annual Scientific Meeting and Exhibition, San Francisco, USA, 1991:233
Hamm B, Taupitz M, Hussmann P, Wagner S, Wolf KJ (1992) MR lymphography with iron oxide particles: dose-response studies and pulse sequence optimization in rabbits. AJR 158: 183–190
Taupitz M, Wagner S, Hamm B, Dienemann D, Lawaczeck R, Wolf KJ (1992) MR lymphography using iron oxide particles: detection of lymph node metastases in the VX2 rabbit tumor model. Acta Radiologica 1993 (in press)
Lee AS, Weissleder R, Wittenberg J, Brady TJ (1991) Lymph nodes: microstructural anatomy by MR imaging. Radiology 178: 519–522
Hahn PF, Stark DD, Saini S, Lewis JM, Wittenberg J, Ferrucci JT (1987) Ferrite particles for bowel contrast in MR imaging: design issues and feasibility studies. Radiology 164: 37
Majumdar S, Zoghbi S, Gore JC (1988) Regional differences in rat brain displayed by fast MRI with superparamagnetic contrast agents. Magn Reson Med 6: 611–615
Kent TA, Quast MJ, Kaplan BJ, Lifsey RS, Eisenberg HM (1990) Assessment of a superparamagnetic iron oxide (AMI-25) as a brain contrast agent. Mag Reson Med 13: 434–443
White DL, Aicher KP, Tzika AA, Kucharzyk J, Engelstad B, Moseley ME (1992) Iron-dextran as a magnetic susceptibility contrast agent: flow-related contrast effects in the T2-weighted spin-echo MRI of normal rat and cat brain. Magn Reson Med 24: 14–28
Bulte JWM, De Jonge MWA, Kamman RL, et al (1992) Dextran-magnetite particles: contrast-enhanced MRI of blood-brain barrier d disruption in a rat model. Mag Reson Med 23: 215–223
Weissleder R, Bogdanov A, Papisov M (1992) Drug targeting in magnetic resonance imaging. Magn Reson Q 8: 55–63
Weissleder R, Lee AS, Khaw BA, Shen T, Brady TJ (1992) Antimyosin-labelled monocrystalline iron oxide allows detection of myocardial infarct: MR antibody imaging. Radiology 182: 381–385
Chan TW, Eley C, Kressel HY (1991) MR imaging of abscess and tumor using lipid-coated iron oxide particles. In: Society of Magnetic Resonance in Medicine, Tenth Annual Meeting, San Francisco, p 54
Tsai E, Bogdanov A, Papisov M, Brady TJ, Weissleder R (1992) Lymphocytes as carriers for MR contrast agents. In: Society of Magnetic Resonance in Medicine, Eleventh Annual Meeting, Berlin. accepted for publication
Chan TW, So A, Kressel HY (1990) In-vitro incorporation of iron oxide particles into peripheral phagocytic cells. In: Society of Magnetic Resonance in Medicine, Ninth Annual Meeting, New York, p 749
Ghosh P, Zhou X, Lin W, Feng AS, Groman E, Lauterbur PC (1991) Neuronal tracing with magnetic labels. In: Society of Magnetic Resonance in Medicine, Tenth Annual Meeting, San Francisco, p 1042
Filler AG, Winn HR, Howe FA, Griffiths JR, Bell BA, Deacon TW (1991) Axonal transport of superparamagnetic metal oxide particle: potential of magnetic resonance assessments of axoplasmic flow in clinical neuroscience. In: Society of Magnetic Resonance in Medicine, Tenth Annual Meeting, San Francisco, pp 985
Achord DT, Brot FE, Sly WS (1977) Inhibition of the rat clearance system for agalacto-orosomucoid by yeast mannans and by mannose. Biochem Biophys Res Commun 77: 409–415
Stahl PD, Rodman JS, Miller MJ, Schlesinger PH (1978) Evidence for receptor-mediated binding of glycoproteins, glycoconjugates, and lysosomal glycosidases by alveolar macrophages. Proc Natl Acad Sci USA 75: 1399–1403
Ashwell G, Harford J (1982) Carbohydrate-specific receptors of the liver. Annu Rev Biochem 51: 531–554
Prieels JP, Pizzo SV, Glasgow LR, Paulson JC, Hill RL (1978) Hepatic receptor that specifically binds oligosaccharides containing fucosyl α1, 3-N-acetylglucosamine linkages. Proc Natl Acad Sci USA 75: 2215–2219
Reimer P, Shen T, Lee AS, Brady TJ, Weissleder R (1992) Effect of polysaccharide coated iron oxide particles on liver relaxation times. In: Society of Magnetic Resonance in Medicine, Eleventh Annual Meeting, Berlin, p 3224
Cerdan S, Lötscher HR, Künnecke B, Seelig J (1989) Monoclonal antibody-coated magnetite particles as contrast agents in magnetic resonance imaging of tumors. Magn Reson Med 12: 151–163
Khaw BA, Bailes JS, Schneider SL, et al (1988) Human breast tumor imaging using 111In labelled monoclonal antibody: athymic mouse model. Eur J Nucl Med 14: 362–366
Author information
Authors and Affiliations
Additional information
Correspondence to: R. Weissleder
Rights and permissions
About this article
Cite this article
Weissleder, R., Reimer, P. Superparamegnetic iron oxides for MRI. Eur. Radiol. 3, 198–212 (1993). https://doi.org/10.1007/BF00425895
Issue Date:
DOI: https://doi.org/10.1007/BF00425895